How to Optimize ECLS Results beyond Ventricular Unloading: From ECMO to CentriMag^® eVAD

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Biomedical Engineering

Background:

• Primary cardiogenic shock requires immediate circulatory support.
• Conventional Extracorporeal Membrane Oxygenation (ECMO) is a standard treatment.
• CentriMag extracorporeal Ventricular Assist Device (VAD) offers a potentially more physiological alternative.

Purpose of the Study:

• To compare the outcomes of CentriMag extracorporeal VAD versus conventional ECMO in patients with primary cardiogenic shock.
• To evaluate the impact of device selection on survival and support duration.

Main Methods:

• Retrospective review of 212 patients with primary cardiogenic shock treated with extracorporeal life support (January 2009-December 2018).
• Comparison between patients treated exclusively with ECMO (n=143) and those with extracorporeal VAD implantation (n=69).
• Analysis of extracorporeal life support duration, highest predicted flow rates, and in-hospital/overall mortality.

Main Results:

• Extracorporeal VAD support duration was significantly longer (14.25 days) than ECMO (8.37 days) (p=0.001).
• Mean highest predicted flow rates were higher with extracorporeal VAD (79.49%) compared to ECMO (61.21%) (p=0.001).
• Increasing mechanical support flow correlated with mortality in ECMO patients but not in extracorporeal VAD patients, with higher survival in the VAD group (p=0.027).

Conclusions:

• CentriMag extracorporeal VAD provides longer and higher-flow mechanical circulatory support compared to ECMO in primary cardiogenic shock.
• Extracorporeal VAD implantation is associated with improved survival, particularly in high-flow support scenarios.
• CentriMag extracorporeal VAD represents a more physiological and effective option for managing primary cardiogenic shock.